Biomarkers in Colorectal Cancer Screening

Authors:
Minhhuyen T. NguyenFrom Fox Chase Cancer Center-Temple Health, Philadelphia, Pennsylvania.

Search for other papers by Minhhuyen T. Nguyen in
Current site
Google Scholar
PubMed
Close
 MD
and
David S. WeinbergFrom Fox Chase Cancer Center-Temple Health, Philadelphia, Pennsylvania.

Search for other papers by David S. Weinberg in
Current site
Google Scholar
PubMed
Close
 MD, MSc
View More View Less
Restricted access

Colorectal cancer (CRC) is the third most common cause of cancer death in men and women in the United States. The main goals of screening are to prevent carcinogenesis (via adenoma detection and removal) and detect cancer at an early, curable stage. CRC mortality is steadily dropping in the United States, partly because of greater screening utilization. However, nearly 1 in 3 average-risk people are not up to date with standard CRC screening recommendations. This review surveys a wide range of CRC biomarkers in various stages of development, which may offer attractive risk stratification tools; a few have reached the commercial stage. If widely accepted, these tools may contribute to shift CRC screening practices away from 1-step colonoscopy to a 2-step risk stratification process of predictive biomarker measurements followed by colonoscopy for lower-risk patients with a positive result. Such strategies could potentially increase the rate of CRC screening.

Correspondence: Minhhuyen T. Nguyen, MD, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111. E-mail: Minhhuyen.Nguyen@fccc.edu

Supplementary Materials

    • Supplemental Material (PDF 149 KB)
  • Collapse
  • Expand
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1482 294 17
PDF Downloads 1058 322 23
EPUB Downloads 0 0 0